For its first fiscal quarter (ending March 31), United Therapeutics Corp (NASDAQ: UTHR) has reported a 25% increase in E.P.S. from $5.20 a year ago to $6.52 in the current quarter. For the latest four quarters through March 31, E.P.S. were $22.38 compared to $15.90 a year ago — an increase of 41%.
Recent Price Action
United Therapeutics Corp (NASDAQ: UTHR) stock enjoyed a very large increase of 8.9% on 5/1/24. The shares closed at $255.14. Moreover, trading volume in this advance was exceptionally high at 267% of normal. The stock has performed in line with the market over the last nine months and has risen 8.8% during the last week.
Current PriceTarget Research Rating
With future capital returns forecasted to be above the cost of capital, UTHR is expected to continue to be an important Value Builder.
United Therapeutics has a current Value Trend Rating of B (Positive). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing inconsistent signals. United Therapeutics has a neutral Power Rating of 52 but a good Appreciation Score of 81, and the Positive Value Trend Rating results.
Rating Review
In light of this new information we are reviewing our current Overall Rating of B. This review will be completed in the next several days.
Be the first to comment